Syros Pharmaceuticals (NASDAQ:SYRS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note released on Monday morning. The brokerage issued a sell rating on the stock.

A number of other research firms have also weighed in on SYRS. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Stock Down 0.5 %

Shares of SYRS stock opened at $0.20 on Monday. The stock’s 50 day simple moving average is $1.09 and its 200 day simple moving average is $2.79. Syros Pharmaceuticals has a twelve month low of $0.18 and a twelve month high of $8.17. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The company has a market capitalization of $5.44 million, a price-to-earnings ratio of -0.07 and a beta of 1.34.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter in the prior year, the business posted ($1.35) earnings per share. As a group, research analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Activity at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the sale, the director now directly owns 41,070 shares in the company, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 12.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SYRS. Exome Asset Management LLC boosted its holdings in Syros Pharmaceuticals by 87.6% during the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares in the last quarter. Certuity LLC acquired a new stake in Syros Pharmaceuticals in the 2nd quarter valued at $109,000. Acadian Asset Management LLC boosted its stake in Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after buying an additional 17,416 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in Syros Pharmaceuticals in the third quarter valued at $34,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.